This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (64)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA

Scott D. Halpern, MSCE; Jason H. T. Karlawish, MD; Jesse A. Berlin, ScD

JAMA. 2002;288:358-362.

Despite long-standing critiques of the conduct of underpowered clinical trials, the practice not only remains widespread, but also has garnered increasing support. Patients and healthy volunteers continue to participate in research that may be of limited clinical value, and authors recently have offered 2 related arguments to support the validity and value of underpowered clinical trials: that meta-analysis may "save" small studies by providing a means to combine the results with those of other similar studies to enable estimates of an intervention's efficacy, and that although small studies may not provide a good basis for testing hypotheses, they may provide valuable estimates of treatment effects using confidence intervals. In this article, we examine these arguments in light of the distinctive moral issues associated with the conduct of underpowered trials, the disclosures that are owed to potential participants in underpowered trials so they may make autonomous enrollment decisions, and the circumstances in which the prospects for future meta-analyses may justify individually underpowered trials. We conclude that underpowered trials are ethical in only 2 situations: small trials of interventions for rare diseases in which investigators document explicit plans for including their results with those of similar trials in a prospective meta-analysis, and early-phase trials in the development of drugs or devices, provided they are adequately powered for defined purposes other than randomized treatment comparisons. In both cases, investigators must inform prospective subjects that their participation may only indirectly contribute to future health care benefits.

Author Affiliations: Center for Clinical Epidemiology and Biostatistics (Mr Halpern and Dr Berlin), Center for Bioethics (Mr Halpern and Dr Karlawish), Center for Education and Research on Therapeutics (Mr Halpern and Dr Berlin), Department of Medicine (Dr Karlawish), and Leonard Davis Institute of Health Economics (Dr Karlawish), University of Pennsylvania School of Medicine, Philadelphia.

RELATED LETTERS

The Ethics of Underpowered Clinical Trials
Janine E. Janosky, John R. Hughes, Richard J. Lilford, Scott D. Halpern, Jason H. T. Karlawish, and Jesse A. Berlin
JAMA. 2002;288(17):2118-2119.
EXTRACT | FULL TEXT  

Underpowered Clinical Trials of Antiretroviral Treatment
Jose R. Arribas, Federico Pulido, Patrick G. Yeni, and Scott M. Hammer
JAMA. 2002;288(17):2120-2121.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Informing Clinical Trial Participants About Study Results
Ann H. Partridge and Eric P. Winer
JAMA. 2002;288(3):363-365.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials
Gomberg-Maitland
Proc Am Thorac Soc 2008;5:610-616.
ABSTRACT | FULL TEXT  

The Ethics of Randomized Clinical Trials in Pulmonary Arterial Hypertension
Halpern et al.
Proc Am Thorac Soc 2008;5:631-635.
ABSTRACT | FULL TEXT  

Statistical Power of Negative Randomized Controlled Trials Presented at American Society for Clinical Oncology Annual Meetings
Bedard et al.
JCO 2007;25:3482-3487.
ABSTRACT | FULL TEXT  

Scaling-Up Exemplary Interventions
McDonald et al.
EDUCATIONAL RESEARCHER 2006;35:15-24.
ABSTRACT  

Payment to healthcare professionals for patient recruitment to trials: a systematic review
Bryant and Powell
BMJ 2005;331:1377-1378.
FULL TEXT  

RE: "ETHICS AND SAMPLE SIZE"
Halpern et al.
Am J Epidemiol 2005;162:195-196.
FULL TEXT  

Reply to the Editor
Sedrakyan and O'Byrne
J. Thorac. Cardiovasc. Surg. 2005;129:1205-1206.
FULL TEXT  

A Review of the True Methodological Quality of Nutritional Support Trials Conducted in the Critically Ill: Time for Improvement
Doig et al.
Anesth. Analg. 2005;100:527-533.
ABSTRACT | FULL TEXT  

Ethics and Sample Size
Bacchetti et al.
Am J Epidemiol 2005;161:105-110.
ABSTRACT | FULL TEXT  

Invited Commentary: Ethics and Sample Size--Another View
Prentice
Am J Epidemiol 2005;161:111-112.
FULL TEXT  

The Ethical Conduct of Clinical Research Involving Critically Ill Patients in the United States and Canada: Principles and Recommendations
Am. J. Respir. Crit. Care Med. 2004;170:1375-1384.
FULL TEXT  

Ten categories of statistical errors: a guide for research in endocrinology and metabolism
Holmes
Am. J. Physiol. Endocrinol. Metab. 2004;286:E495-E501.
ABSTRACT | FULL TEXT  

Sample Size Estimation in Research With Dependent Measures and Dichotomous Outcomes
Delucchi
Am. J. Public Health 2004;94:372-377.
ABSTRACT | FULL TEXT  

Sample Size Estimation: A Glimpse beyond Simple Formulas
Eng
Radiology 2004;230:606-612.
ABSTRACT | FULL TEXT  

Herbals and Botanicals in Geriatric Psychiatry
Desai and Grossberg
AJGP 2003;11:498-506.
ABSTRACT | FULL TEXT  

Effect of Communications Training on Medical Student Performance
Yedidia et al.
JAMA 2003;290:1157-1165.
ABSTRACT | FULL TEXT  

Missing the (Acu) Point
Caspi et al.
Chest 2003;123:1312-1314.
FULL TEXT  

Magnesium Sulfate for Mild Preeclampsia
Scott
Obstet Gynecol 2003;101:213-213.
FULL TEXT  

Preoperative Chemoradiation for Rectal Cancer: A Different Perspective
Bozzetti
Ann. Surg. Oncol. 2002;9:1033-1034.
FULL TEXT  

The Ethics of Underpowered Clinical Trials
Janosky et al.
JAMA 2002;288:2118-2119.
FULL TEXT  

Underpowered Clinical Trials of Antiretroviral Treatment
Arribas et al.
JAMA 2002;288:2120-2121.
FULL TEXT  

Robin Goodfellow
Rheumatology (Oxford) 2002;41:1081-1081.
FULL TEXT